DrugDashboards

Cisatracurium Besylate

Cisatracurium Besylate · CISATRACURIUM BESYLATE 10 mg/mL · Injection · Intravenous · Somerset Therapeutics, LLC

NDC 70069-0151-01 · 1 VIAL in 1 CARTON / 20 mL in 1 VIAL · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply. One of its named manufacturing plants, Somerset Therapeutics Private Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA206791
TE code
AP
Approval date
Feb 20, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · OngoingNov 26, 2025
    SOMERSET THERAPEUTICS LLC — Subpotent product:out of specification assay results observed during long term stability testing.
  • Class III · OngoingNov 26, 2025
    SOMERSET THERAPEUTICS LLC — Subpotent product:out of specification assay results observed during long term stability testing.

Manufacturers of Cisatracurium Besylate (Injection)

LabelerStrengthFirst seenLast seen
Camber Pharmaceuticals Inc.CISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Caplin Steriles LimitedCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Slate Run Pharmaceuticals, LLCCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Somerset Therapeutics, LLCCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Armas PharmaceuticalsCISATRACURIUM BESYLATE 200 mg/20mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals Inc.CISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCCISATRACURIUM BESYLATE 10 mg/5mLJul 15, 2026Sep 2, 2026
Eugia US LLCCISATRACURIUM BESYLATE 20 mg/10mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Sandoz IncCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Slate Run Pharmaceuticals, LLCCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Somerset Therapeutics, LLCCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.CISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Aug 31, 2026
Sandoz IncCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Cisatracurium Besylate — NDC 70069-0151-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70069015101.

Free to cite with attribution — see how the data is put together.